Boston Advisors LLC boosted its stake in Clorox Co. (NYSE:CLX) by 14.3% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 196,360 shares of the company’s stock after buying an additional 24,501 shares during the period. Boston Advisors LLC’s holdings in Clorox were worth $27,174,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Cullen Frost Bankers Inc. boosted its stake in Clorox by 1.9% in the second quarter. Cullen Frost Bankers Inc. now owns 49,604 shares of the company’s stock valued at $6,865,000 after buying an additional 923 shares during the period. NewSquare Capital LLC boosted its stake in Clorox by 15.2% in the second quarter. NewSquare Capital LLC now owns 3,729 shares of the company’s stock valued at $516,000 after buying an additional 493 shares during the period. Pitcairn Co. boosted its stake in Clorox by 3.4% in the second quarter. Pitcairn Co. now owns 8,634 shares of the company’s stock valued at $1,195,000 after buying an additional 284 shares during the period. Destination Wealth Management boosted its stake in Clorox by 165.6% in the second quarter. Destination Wealth Management now owns 18,192 shares of the company’s stock valued at $2,518,000 after buying an additional 11,342 shares during the period. Finally, Albion Financial Group UT boosted its stake in Clorox by 1.1% in the second quarter. Albion Financial Group UT now owns 39,629 shares of the company’s stock valued at $5,484,000 after buying an additional 436 shares during the period. Institutional investors own 70.26% of the company’s stock.

Clorox Co. (NYSE:CLX) traded up 1.74% during trading on Thursday, reaching $126.57. 1,375,237 shares of the company’s stock traded hands. The stock has a market capitalization of $16.39 billion, a P/E ratio of 25.73 and a beta of 0.33. The company has a 50-day moving average of $129.33 and a 200 day moving average of $130.06. Clorox Co. has a 12 month low of $113.37 and a 12 month high of $140.47.

Clorox (NYSE:CLX) last posted its quarterly earnings data on Wednesday, August 3rd. The company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.28 by $0.02. The company earned $1.60 billion during the quarter, compared to analyst estimates of $1.58 billion. Clorox had a return on equity of 296.91% and a net margin of 11.25%. The business’s revenue for the quarter was up 2.8% compared to the same quarter last year. During the same period in the previous year, the company earned $1.44 EPS. On average, equities research analysts expect that Clorox Co. will post $5.49 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 14th. Investors of record on Wednesday, October 26th will be issued a $0.80 dividend. This represents a $3.20 annualized dividend and a yield of 2.53%. The ex-dividend date of this dividend is Monday, October 24th. Clorox’s payout ratio is currently 64.91%.

Several research firms have recently commented on CLX. Atlantic Securities upgraded shares of Clorox from a “hold” rating to a “buy” rating and set a $144.00 target price for the company in a research note on Friday, September 16th. B. Riley restated a “neutral” rating and issued a $109.00 target price on shares of Clorox in a research note on Tuesday, August 9th. Citigroup Inc. raised their target price on shares of Clorox from $134.00 to $144.00 and gave the stock a “neutral” rating in a research note on Monday, August 8th. Zacks Investment Research upgraded shares of Clorox from a “hold” rating to a “buy” rating and set a $148.00 target price for the company in a research note on Monday, August 8th. Finally, Goldman Sachs Group Inc. restated a “neutral” rating and issued a $130.00 target price on shares of Clorox in a research note on Thursday, August 4th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and two have issued a buy rating to the company’s stock. Clorox has an average rating of “Hold” and an average price target of $128.90.

In other Clorox news, EVP Laura Stein sold 38,882 shares of the company’s stock in a transaction dated Friday, September 2nd. The shares were sold at an average price of $131.69, for a total value of $5,120,370.58. Following the completion of the sale, the executive vice president now directly owns 48,501 shares of the company’s stock, valued at approximately $6,387,096.69. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Dawn C. Willoughby sold 10,617 shares of the company’s stock in a transaction dated Wednesday, August 17th. The shares were sold at an average price of $131.01, for a total transaction of $1,390,933.17. Following the completion of the sale, the chief operating officer now directly owns 20,353 shares of the company’s stock, valued at $2,666,446.53. The disclosure for this sale can be found here. 2.09% of the stock is currently owned by corporate insiders.

About Clorox

The Clorox Company is a manufacturer and marketer of consumer and professional products. The Company sells its products primarily through mass retail outlets, e-commerce channels, wholesale distributors and medical supply distributors. The Company operates through four segments: Cleaning, Household, Lifestyle and International.

5 Day Chart for NYSE:CLX

Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clorox Co. (NYSE:CLX).

Receive News & Ratings for Clorox Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox Co. and related companies with MarketBeat.com's FREE daily email newsletter.